Simple IV drip may prevent painful complication after common bile duct procedure

NCT ID NCT06260878

Recruiting now Prevention Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a short course of intravenous Ringer's lactate fluid around the time of an ERCP procedure can prevent pancreatitis, a common and serious side effect. Researchers will enroll 505 adults aged 18-75 who are having their first ERCP. Participants will receive the IV fluid and be monitored for signs of pancreatitis the next day.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Intravenous Ringer's lactate
What this could lead to: If successful, this could provide a simple, low-cost way to prevent a common and serious complication of ERCP, reducing hospital stays and improving patient outcomes.
What could go wrong: This is a single-center trial with 505 participants, so results may not apply to all patients. The benefit may be small or absent, and there is a risk of fluid overload in some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-ERCP ACUTE PANCREATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute pancreatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-ERCP ACUTE PANCREATITIS

Contacts and locations

Locations

Peter Lougheed Centre
RECRUITING

Calgary, Alberta, T1Y 6J4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.